ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism

Nature Chemical Biology

Volumn 3, Issue 11, 2007, Pages 722-726

  Luo, Lusong ^a   Parrish, Cynthia A ^a   Nevins, Neysa ^b   McNulty, Dean E ^b   Chaudhari, Amita M ^a   Carson, Jeffery D ^a   Sudakin, Valery ^a   Shaw, Antony N ^a   Lehr, Ruth ^c   Zhao, Huizhen ^c   Sweitzer, Sharon ^c   Lad, Latesh ^d   Wood, Kenneth W ^d   Sakowicz, Roman ^d   Annan, Roland S ^b   Huang, Pearl S ^a,e   Jackson, Jeffrey R ^a   Dhanak, Dashyant ^a   Copeland, Robert A ^a   Auger, Kurt R ^a  

^a Oncology CEDD ^*  (United States)

^b Molecular Discovery Research   (United States)

^c GLAXOSMITHKLINE   (United States)

^d Cytokinetics Inc   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; EG5 PROTEIN; ISPINESIB; KINESIN; KINESIN SPINDLE PROTEIN; KINESIN SPINDLE PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; HUMAN; NUCLEOTIDE BINDING SITE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; SITE DIRECTED MUTAGENESIS;

EID: 35349018479     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2007.34     Document Type: Article

References (27)

1. Kapitein, L.C. et al. The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature 435, 114-118 (2005).
2. Kapoor, T.M., Mayer, T.U., Coughlin, M.L. & Mitchison, T.J. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J. Cell Biol. 150, 975-988 (2000).
3. Sakowicz, R. et al. Antitumor activity of a kinesin inhibitor. Cancer Res. 64, 3276-3280 (2004).
4. Bergnes, G., Brejc, K. & Belmont, L. Mitotic kinesins: prospects for antimitotic drug discovery. Curr. Top. Med. Chem. 5, 127-145 (2005).
5. Jackson, J.R., Patrick, D.R., Dar, M.M. & Huang, P.S. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat. Rev. Cancer 7, 107-117 (2007).
6. Brier, S., Lemaire, D., DeBonis, S., Forest, E. & Kozielski, F. Identification of the protein binding region of S-trityl-l-cysteine, a new potent inhibitor of the mitotic kinesin Eg5. Biochemistry 43, 13072-13082 (2004).
7. Cochran, J.C., Gatial, J.E., III, Kapoor, T.M. & Gilbert, S.P. Monastrol inhibition of the mitotic kinesin Eg5. J. Biol. Chem. 280, 12658-12667 (2005).
8. Cox, C.D. et al. Kinesin spindle protein (KSP) inhibitors. Part 1: the discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg. Med. Chem. Lett. 15, 2041-2045 (2005).
9. Cox, C.D. et al. Kinesin spindle protein (KSP) inhibitors. Part 4: structure-based design of 5-alkylamino-3,5-diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP. Bioorg. Med. Chem. Lett. 16, 3175-3179 (2006).
10. Luo, L. et al. Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition. Biochemistry 43, 15258-15266 (2004).
11. Mayer, T.U. et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286, 971-974 (1999).
12. Skoufias, D.A. et al. S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. J. Biol. Chem. 281, 17559-17569 (2006).
13. Yan, Y. et al. Inhibition of a mitotic motor protein: where, how, and conformational consequences. J. Mol. Biol. 335, 547-554 (2004).
14. Brier, S., Lemaire, D., DeBonis, S., Forest, E. & Kozielski, F. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents. J. Mol. Biol. 360, 360-376 (2006).
15. Jackson, J.R. et al. in Proceedings of the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting. Philadelphia, PA, November 14-18, 2005 (AACR, Philadelphia, 2005).
16. Maliga, Z. & Mitchison, T.J. Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol. BMC Chem. Biol. 6, 2 (2006).
17. Parrish, C.A. et al. Novel ATP-competitive kinesin spindle protein inhibitors. J. Med. Chem. published online 29 August 2007 (doi:10.1021/jm070435y).
18. Copeland, R.A., Luo, L., Auger, K.R. & Huang, P.S. A method for determining intracellular concentrations of enzyme substrates from a combination of competitive inhibition and mutagenesis studies. Anal. Biochem. 337, 351-353 (2005).
19. Deininger, M. Resistance to imatinib: mechanisms and management. J. Natl. Compr. Canc. Netw. 3, 757-768 (2005).
20. Mellinghoff, I.K. & Sawyers, C.L. The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics 3, 603-623 (2002).
21. Nitta, R., Kikkawa, M., Okada, Y. & Hirokawa, N. KIF1A alternately uses two loops to bind microtubules. Science 305, 678-683 (2004).
22. Tomishige, M., Stuurman, N. & Vale, R.D. Single-molecule observations of neck linker conformational changes in the kinesin motor protein. Nat. Struct. Mol. Biol. 13, 887-894 (2006).
23. Rice, S. et al. A structural change in the kinesin motor protein that drives motility. Nature 402, 778-784 (1999).
24. Kull, F.J. & Endow, S.A. A new structural state of myosin. Trends Biochem. Sci. 29, 103-106 (2004).
25. Bacheler, L.T. Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase. Drug Resist. Updat. 2, 56-67 (1999).
26. Basavapathruni, A., Bailey, C.M. & Anderson, K.S. Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J. Biol. Chem. 279, 6221-6224 (2004).
27. Zhu, Q.Y., Scarborough, A., Polsky, B. & Chou, T.C. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. AIDS Res. Hum. Retroviruses 12, 507-517 (1996).